SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes. Currently there are no validated noninvasive diagnostics that can diff...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2021-05-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1670 |
| _version_ | 1797936759132127232 |
|---|---|
| author | Yi Luo Samir Wadhawan Alex Greenfield Benjamin E. Decato Abdul M. Oseini Rebecca Collen Diane E. Shevell John Thompson Gabor Jarai Edgar D. Charles Arun J. Sanyal |
| author_facet | Yi Luo Samir Wadhawan Alex Greenfield Benjamin E. Decato Abdul M. Oseini Rebecca Collen Diane E. Shevell John Thompson Gabor Jarai Edgar D. Charles Arun J. Sanyal |
| author_sort | Yi Luo |
| collection | DOAJ |
| description | Nonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes. Currently there are no validated noninvasive diagnostics that can differentiate between fibrosis stages in patients with NASH; many existing tests do not reflect underlying disease pathophysiology. Noninvasive biomarkers are needed to identify patients at high‐risk of NASH with advanced fibrosis. This was a retrospective study of patients with histologically proven NASH with fibrosis stages 0‐4. The SOMAscan proteomics platform was used to quantify 1,305 serum proteins in a discovery cohort (n = 113). In patients with advanced (stages 3‐4) versus early fibrosis (stages 0‐2), 97 proteins with diverse biological functions were differentially expressed. Next, fibrosis‐stage classification models were explored using a machine learning–based approach to prioritize the biomarkers for further evaluation. A four‐protein model differentiated patients with stage 0‐1 versus stage 2‐4 fibrosis (area under the receiver operating characteristic curve [AUROC] = 0.74), while a 12‐protein classifier differentiated advanced versus early fibrosis (AUROC = 0.83). Subsequently, the model’s performance was validated in two independent cohorts (n = 71 and n = 32) with similar results (AUROC = 0.74‐0.78). Our advanced fibrosis model performed similarly to or better than Fibrosis‐4 index, aspartate aminotransferase–to‐platelet ratio index, and nonalcoholic fatty liver disease (NAFLD) fibrosis score–based models for all three cohorts. Conclusion: A SOMAscan proteomics‐based exploratory classifier for advanced fibrosis, consisting of biomarkers that reflect the complexity of NASH pathophysiology, demonstrated similar performance in independent validation cohorts and performed similarly or better than Fibrosis‐4 index, aspartate aminotransferase–to‐platelet ratio index, and NAFLD fibrosis score. Further studies are warranted to evaluate the clinical utility of these biomarker panels in patients with NAFLD. |
| first_indexed | 2024-04-10T18:35:05Z |
| format | Article |
| id | doaj.art-8a3abd3b1df443e39f2096123e2609aa |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-04-10T18:35:05Z |
| publishDate | 2021-05-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-8a3abd3b1df443e39f2096123e2609aa2023-02-02T01:49:55ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2021-05-015576077310.1002/hep4.1670SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASHYi Luo0Samir Wadhawan1Alex Greenfield2Benjamin E. Decato3Abdul M. Oseini4Rebecca Collen5Diane E. Shevell6John Thompson7Gabor Jarai8Edgar D. Charles9Arun J. Sanyal10Bristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USAVirginia Commonwealth University Richmond VA USAVirginia Commonwealth University Richmond VA USABristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USABristol Myers Squibb Princeton NJ USAVirginia Commonwealth University Richmond VA USANonalcoholic steatohepatitis (NASH) is a major cause of liver‐related morbidity and mortality worldwide. Liver fibrosis stage, a key component of NASH, has been linked to the risk of mortality and liver‐related clinical outcomes. Currently there are no validated noninvasive diagnostics that can differentiate between fibrosis stages in patients with NASH; many existing tests do not reflect underlying disease pathophysiology. Noninvasive biomarkers are needed to identify patients at high‐risk of NASH with advanced fibrosis. This was a retrospective study of patients with histologically proven NASH with fibrosis stages 0‐4. The SOMAscan proteomics platform was used to quantify 1,305 serum proteins in a discovery cohort (n = 113). In patients with advanced (stages 3‐4) versus early fibrosis (stages 0‐2), 97 proteins with diverse biological functions were differentially expressed. Next, fibrosis‐stage classification models were explored using a machine learning–based approach to prioritize the biomarkers for further evaluation. A four‐protein model differentiated patients with stage 0‐1 versus stage 2‐4 fibrosis (area under the receiver operating characteristic curve [AUROC] = 0.74), while a 12‐protein classifier differentiated advanced versus early fibrosis (AUROC = 0.83). Subsequently, the model’s performance was validated in two independent cohorts (n = 71 and n = 32) with similar results (AUROC = 0.74‐0.78). Our advanced fibrosis model performed similarly to or better than Fibrosis‐4 index, aspartate aminotransferase–to‐platelet ratio index, and nonalcoholic fatty liver disease (NAFLD) fibrosis score–based models for all three cohorts. Conclusion: A SOMAscan proteomics‐based exploratory classifier for advanced fibrosis, consisting of biomarkers that reflect the complexity of NASH pathophysiology, demonstrated similar performance in independent validation cohorts and performed similarly or better than Fibrosis‐4 index, aspartate aminotransferase–to‐platelet ratio index, and NAFLD fibrosis score. Further studies are warranted to evaluate the clinical utility of these biomarker panels in patients with NAFLD.https://doi.org/10.1002/hep4.1670 |
| spellingShingle | Yi Luo Samir Wadhawan Alex Greenfield Benjamin E. Decato Abdul M. Oseini Rebecca Collen Diane E. Shevell John Thompson Gabor Jarai Edgar D. Charles Arun J. Sanyal SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH Hepatology Communications |
| title | SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH |
| title_full | SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH |
| title_fullStr | SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH |
| title_full_unstemmed | SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH |
| title_short | SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH |
| title_sort | somascan proteomics identifies serum biomarkers associated with liver fibrosis in patients with nash |
| url | https://doi.org/10.1002/hep4.1670 |
| work_keys_str_mv | AT yiluo somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT samirwadhawan somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT alexgreenfield somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT benjaminedecato somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT abdulmoseini somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT rebeccacollen somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT dianeeshevell somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT johnthompson somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT gaborjarai somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT edgardcharles somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash AT arunjsanyal somascanproteomicsidentifiesserumbiomarkersassociatedwithliverfibrosisinpatientswithnash |